Abstract
Summary
According to our LPI (LP Information) latest study, the global Human Vaccine market size was valued at US$ 31250 million in 2023. With growing demand in downstream market, the Human Vaccine is forecast to a readjusted size of US$ 43440 million by 2030 with a CAGR of 4.8% during review period. _x000D_
The research report highlights the growth potential of the global Human Vaccine market. Human Vaccine are expected to show stable growth in the future market. However, product differentiation, reducing costs, and supply chain optimization remain crucial for the widespread adoption of Human Vaccine. Market players need to invest in research and development, forge strategic partnerships, and align their offerings with evolving consumer preferences to capitalize on the immense opportunities presented by the Human Vaccine market._x000D_
A vaccine is a biological preparation that provides active acquired immunity to a particular disease. A vaccine typically contains an agent that resembles a disease-causing microorganism and is often made from weakened or killed forms of the microbe, its toxins or one of its surface proteins._x000D_
In China, Human Vaccine key players include CNBG, Kangtai, ChengDa Bio, etc. Global top three manufacturers hold a share about 65%.
East China is the largest market, with a share about 25%, followed by South China, and North China, both have a share about 40 percent.
In terms of product, Hepatitis B is the largest segment, with a share nearly 15%. And in terms of application, the largest application is Children, followed by Adults._x000D_
Key Features:_x000D_
The report on Human Vaccine market reflects various aspects and provide valuable insights into the industry._x000D_
Market Size and Growth: The research report provide an overview of the current size and growth of the Human Vaccine market. It may include historical data, market segmentation by Type (e.g., Varicella, Influenza), and regional breakdowns._x000D_
Market Drivers and Challenges: The report can identify and analyse the factors driving the growth of the Human Vaccine market, such as government regulations, environmental concerns, technological advancements, and changing consumer preferences. It can also highlight the challenges faced by the industry, including infrastructure limitations, range anxiety, and high upfront costs._x000D_
Competitive Landscape: The research report provides analysis of the competitive landscape within the Human Vaccine market. It includes profiles of key players, their market share, strategies, and product offerings. The report can also highlight emerging players and their potential impact on the market._x000D_
Technological Developments: The research report can delve into the latest technological developments in the Human Vaccine industry. This include advancements in Human Vaccine technology, Human Vaccine new entrants, Human Vaccine new investment, and other innovations that are shaping the future of Human Vaccine._x000D_
Downstream Procumbent Preference: The report can shed light on customer procumbent behaviour and adoption trends in the Human Vaccine market. It includes factors influencing customer ' purchasing decisions, preferences for Human Vaccine product._x000D_
Government Policies and Incentives: The research report analyse the impact of government policies and incentives on the Human Vaccine market. This may include an assessment of regulatory frameworks, subsidies, tax incentives, and other measures aimed at promoting Human Vaccine market. The report also evaluates the effectiveness of these policies in driving market growth._x000D_
Environmental Impact and Sustainability: The research report assess the environmental impact and sustainability aspects of the Human Vaccine market. _x000D_
Market Forecasts and Future Outlook: Based on the analysis conducted, the research report provide market forecasts and outlook for the Human Vaccine industry. This includes projections of market size, growth rates, regional trends, and predictions on technological advancements and policy developments._x000D_
Recommendations and Opportunities: The report conclude with recommendations for industry stakeholders, policymakers, and investors. It highlights potential opportunities for market players to capitalize on emerging trends, overcome challenges, and contribute to the growth and development of the Human Vaccine market._x000D_
Market Segmentation:_x000D_
Human Vaccine market is split by Type and by Application. For the period 2019-2030, the growth among segments provides accurate calculations and forecasts for consumption value by Type, and by Application in terms of volume and value._x000D_
Segmentation by type_x000D_
Varicella_x000D_
Influenza_x000D_
Polio_x000D_
Hepatitis A_x000D_
Rabies_x000D_
BCG_x000D_
Hepatitis B_x000D_
Pertussis, Diphtheria, Tetanus_x000D_
Pneumococcal_x000D_
Rota vaccine_x000D_
Segmentation by application_x000D_
Adults_x000D_
Children_x000D_
This report also splits the market by region:_x000D_
Americas_x000D_
United States_x000D_
Canada_x000D_
Mexico_x000D_
Brazil_x000D_
APAC_x000D_
China_x000D_
Japan_x000D_
Korea_x000D_
Southeast Asia_x000D_
India_x000D_
Australia_x000D_
Europe_x000D_
Germany_x000D_
France_x000D_
UK_x000D_
Italy_x000D_
Russia_x000D_
Middle East & Africa_x000D_
Egypt_x000D_
South Africa_x000D_
Israel_x000D_
Turkey_x000D_
GCC Countries_x000D_
The below companies that are profiled have been selected based on inputs gathered from primary experts and analyzing the company's coverage, product portfolio, its market penetration._x000D_
CNBG_x000D_
Changsheng Life_x000D_
Zhifei_x000D_
ChengDa Bio_x000D_
Kangtai_x000D_
SINOVAC BIOTECH_x000D_
Hissen_x000D_
Walvax Biotechnology_x000D_
GSK_x000D_
SANOFI_x000D_
Rong An_x000D_
NuoCheng Bio_x000D_
Hualan Bio_x000D_
Tiantan biological_x000D_
Changchun Baike_x000D_
Adimmune_x000D_
Zhongyianke Biotech_x000D_
Bharat Biotech_x000D_
Bavarian Nordic_x000D_
Sanofi-Pasteur_x000D_
Indian Immunologicals_x000D_
KANGH_x000D_
Henan Grand Biopharma_x000D_
ZhongKe Biopharm_x000D_
Zhuoyi Biological_x000D_
Key Questions Addressed in this Report_x000D_
What is the 10-year outlook for the global Human Vaccine market?_x000D_
What factors are driving Human Vaccine market growth, globally and by region?_x000D_
Which technologies are poised for the fastest growth by market and region?_x000D_
How do Human Vaccine market opportunities vary by end market size?_x000D_
How does Human Vaccine break out type, application?_x000D_
Table of Contents
1 Scope of the Report
1.1 Market Introduction
1.2 Years Considered
1.3 Research Objectives
1.4 Market Research Methodology
1.5 Research Process and Data Source
1.6 Economic Indicators
1.7 Currency Considered
1.8 Market Estimation Caveats
2 Executive Summary
2.1 World Market Overview
2.1.1 Global Human Vaccine Annual Sales 2019-2030
2.1.2 World Current & Future Analysis for Human Vaccine by Geographic Region, 2019, 2023 & 2030
2.1.3 World Current & Future Analysis for Human Vaccine by Country/Region, 2019, 2023 & 2030
2.2 Human Vaccine Segment by Type
2.2.1 Varicella
2.2.2 Influenza
2.2.3 Polio
2.2.4 Hepatitis A
2.2.5 Rabies
2.2.6 BCG
2.2.7 Hepatitis B
2.2.8 Pertussis, Diphtheria, Tetanus
2.2.9 Pneumococcal
2.2.10 Rota vaccine
2.3 Human Vaccine Sales by Type
2.3.1 Global Human Vaccine Sales Market Share by Type (2019-2024)
2.3.2 Global Human Vaccine Revenue and Market Share by Type (2019-2024)
2.3.3 Global Human Vaccine Sale Price by Type (2019-2024)
2.4 Human Vaccine Segment by Application
2.4.1 Adults
2.4.2 Children
2.5 Human Vaccine Sales by Application
2.5.1 Global Human Vaccine Sale Market Share by Application (2019-2024)
2.5.2 Global Human Vaccine Revenue and Market Share by Application (2019-2024)
2.5.3 Global Human Vaccine Sale Price by Application (2019-2024)
3 Global Human Vaccine by Company
3.1 Global Human Vaccine Breakdown Data by Company
3.1.1 Global Human Vaccine Annual Sales by Company (2019-2024)
3.1.2 Global Human Vaccine Sales Market Share by Company (2019-2024)
3.2 Global Human Vaccine Annual Revenue by Company (2019-2024)
3.2.1 Global Human Vaccine Revenue by Company (2019-2024)
3.2.2 Global Human Vaccine Revenue Market Share by Company (2019-2024)
3.3 Global Human Vaccine Sale Price by Company
3.4 Key Manufacturers Human Vaccine Producing Area Distribution, Sales Area, Product Type
3.4.1 Key Manufacturers Human Vaccine Product Location Distribution
3.4.2 Players Human Vaccine Products Offered
3.5 Market Concentration Rate Analysis
3.5.1 Competition Landscape Analysis
3.5.2 Concentration Ratio (CR3, CR5 and CR10) & (2019-2024)
3.6 New Products and Potential Entrants
3.7 Mergers & Acquisitions, Expansion
4 World Historic Review for Human Vaccine by Geographic Region
4.1 World Historic Human Vaccine Market Size by Geographic Region (2019-2024)
4.1.1 Global Human Vaccine Annual Sales by Geographic Region (2019-2024)
4.1.2 Global Human Vaccine Annual Revenue by Geographic Region (2019-2024)
4.2 World Historic Human Vaccine Market Size by Country/Region (2019-2024)
4.2.1 Global Human Vaccine Annual Sales by Country/Region (2019-2024)
4.2.2 Global Human Vaccine Annual Revenue by Country/Region (2019-2024)
4.3 Americas Human Vaccine Sales Growth
4.4 APAC Human Vaccine Sales Growth
4.5 Europe Human Vaccine Sales Growth
4.6 Middle East & Africa Human Vaccine Sales Growth
5 Americas
5.1 Americas Human Vaccine Sales by Country
5.1.1 Americas Human Vaccine Sales by Country (2019-2024)
5.1.2 Americas Human Vaccine Revenue by Country (2019-2024)
5.2 Americas Human Vaccine Sales by Type
5.3 Americas Human Vaccine Sales by Application
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Brazil
6 APAC
6.1 APAC Human Vaccine Sales by Region
6.1.1 APAC Human Vaccine Sales by Region (2019-2024)
6.1.2 APAC Human Vaccine Revenue by Region (2019-2024)
6.2 APAC Human Vaccine Sales by Type
6.3 APAC Human Vaccine Sales by Application
6.4 China
6.5 Japan
6.6 South Korea
6.7 Southeast Asia
6.8 India
6.9 Australia
6.10 China Taiwan
7 Europe
7.1 Europe Human Vaccine by Country
7.1.1 Europe Human Vaccine Sales by Country (2019-2024)
7.1.2 Europe Human Vaccine Revenue by Country (2019-2024)
7.2 Europe Human Vaccine Sales by Type
7.3 Europe Human Vaccine Sales by Application
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia
8 Middle East & Africa
8.1 Middle East & Africa Human Vaccine by Country
8.1.1 Middle East & Africa Human Vaccine Sales by Country (2019-2024)
8.1.2 Middle East & Africa Human Vaccine Revenue by Country (2019-2024)
8.2 Middle East & Africa Human Vaccine Sales by Type
8.3 Middle East & Africa Human Vaccine Sales by Application
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries
9 Market Drivers, Challenges and Trends
9.1 Market Drivers & Growth Opportunities
9.2 Market Challenges & Risks
9.3 Industry Trends
10 Manufacturing Cost Structure Analysis
10.1 Raw Material and Suppliers
10.2 Manufacturing Cost Structure Analysis of Human Vaccine
10.3 Manufacturing Process Analysis of Human Vaccine
10.4 Industry Chain Structure of Human Vaccine
11 Marketing, Distributors and Customer
11.1 Sales Channel
11.1.1 Direct Channels
11.1.2 Indirect Channels
11.2 Human Vaccine Distributors
11.3 Human Vaccine Customer
12 World Forecast Review for Human Vaccine by Geographic Region
12.1 Global Human Vaccine Market Size Forecast by Region
12.1.1 Global Human Vaccine Forecast by Region (2025-2030)
12.1.2 Global Human Vaccine Annual Revenue Forecast by Region (2025-2030)
12.2 Americas Forecast by Country
12.3 APAC Forecast by Region
12.4 Europe Forecast by Country
12.5 Middle East & Africa Forecast by Country
12.6 Global Human Vaccine Forecast by Type
12.7 Global Human Vaccine Forecast by Application
13 Key Players Analysis
13.1 CNBG
13.1.1 CNBG Company Information
13.1.2 CNBG Human Vaccine Product Portfolios and Specifications
13.1.3 CNBG Human Vaccine Sales, Revenue, Price and Gross Margin (2019-2024)
13.1.4 CNBG Main Business Overview
13.1.5 CNBG Latest Developments
13.2 Changsheng Life
13.2.1 Changsheng Life Company Information
13.2.2 Changsheng Life Human Vaccine Product Portfolios and Specifications
13.2.3 Changsheng Life Human Vaccine Sales, Revenue, Price and Gross Margin (2019-2024)
13.2.4 Changsheng Life Main Business Overview
13.2.5 Changsheng Life Latest Developments
13.3 Zhifei
13.3.1 Zhifei Company Information
13.3.2 Zhifei Human Vaccine Product Portfolios and Specifications
13.3.3 Zhifei Human Vaccine Sales, Revenue, Price and Gross Margin (2019-2024)
13.3.4 Zhifei Main Business Overview
13.3.5 Zhifei Latest Developments
13.4 ChengDa Bio
13.4.1 ChengDa Bio Company Information
13.4.2 ChengDa Bio Human Vaccine Product Portfolios and Specifications
13.4.3 ChengDa Bio Human Vaccine Sales, Revenue, Price and Gross Margin (2019-2024)
13.4.4 ChengDa Bio Main Business Overview
13.4.5 ChengDa Bio Latest Developments
13.5 Kangtai
13.5.1 Kangtai Company Information
13.5.2 Kangtai Human Vaccine Product Portfolios and Specifications
13.5.3 Kangtai Human Vaccine Sales, Revenue, Price and Gross Margin (2019-2024)
13.5.4 Kangtai Main Business Overview
13.5.5 Kangtai Latest Developments
13.6 SINOVAC BIOTECH
13.6.1 SINOVAC BIOTECH Company Information
13.6.2 SINOVAC BIOTECH Human Vaccine Product Portfolios and Specifications
13.6.3 SINOVAC BIOTECH Human Vaccine Sales, Revenue, Price and Gross Margin (2019-2024)
13.6.4 SINOVAC BIOTECH Main Business Overview
13.6.5 SINOVAC BIOTECH Latest Developments
13.7 Hissen
13.7.1 Hissen Company Information
13.7.2 Hissen Human Vaccine Product Portfolios and Specifications
13.7.3 Hissen Human Vaccine Sales, Revenue, Price and Gross Margin (2019-2024)
13.7.4 Hissen Main Business Overview
13.7.5 Hissen Latest Developments
13.8 Walvax Biotechnology
13.8.1 Walvax Biotechnology Company Information
13.8.2 Walvax Biotechnology Human Vaccine Product Portfolios and Specifications
13.8.3 Walvax Biotechnology Human Vaccine Sales, Revenue, Price and Gross Margin (2019-2024)
13.8.4 Walvax Biotechnology Main Business Overview
13.8.5 Walvax Biotechnology Latest Developments
13.9 GSK
13.9.1 GSK Company Information
13.9.2 GSK Human Vaccine Product Portfolios and Specifications
13.9.3 GSK Human Vaccine Sales, Revenue, Price and Gross Margin (2019-2024)
13.9.4 GSK Main Business Overview
13.9.5 GSK Latest Developments
13.10 SANOFI
13.10.1 SANOFI Company Information
13.10.2 SANOFI Human Vaccine Product Portfolios and Specifications
13.10.3 SANOFI Human Vaccine Sales, Revenue, Price and Gross Margin (2019-2024)
13.10.4 SANOFI Main Business Overview
13.10.5 SANOFI Latest Developments
13.11 Rong An
13.11.1 Rong An Company Information
13.11.2 Rong An Human Vaccine Product Portfolios and Specifications
13.11.3 Rong An Human Vaccine Sales, Revenue, Price and Gross Margin (2019-2024)
13.11.4 Rong An Main Business Overview
13.11.5 Rong An Latest Developments
13.12 NuoCheng Bio
13.12.1 NuoCheng Bio Company Information
13.12.2 NuoCheng Bio Human Vaccine Product Portfolios and Specifications
13.12.3 NuoCheng Bio Human Vaccine Sales, Revenue, Price and Gross Margin (2019-2024)
13.12.4 NuoCheng Bio Main Business Overview
13.12.5 NuoCheng Bio Latest Developments
13.13 Hualan Bio
13.13.1 Hualan Bio Company Information
13.13.2 Hualan Bio Human Vaccine Product Portfolios and Specifications
13.13.3 Hualan Bio Human Vaccine Sales, Revenue, Price and Gross Margin (2019-2024)
13.13.4 Hualan Bio Main Business Overview
13.13.5 Hualan Bio Latest Developments
13.14 Tiantan biological
13.14.1 Tiantan biological Company Information
13.14.2 Tiantan biological Human Vaccine Product Portfolios and Specifications
13.14.3 Tiantan biological Human Vaccine Sales, Revenue, Price and Gross Margin (2019-2024)
13.14.4 Tiantan biological Main Business Overview
13.14.5 Tiantan biological Latest Developments
13.15 Changchun Baike
13.15.1 Changchun Baike Company Information
13.15.2 Changchun Baike Human Vaccine Product Portfolios and Specifications
13.15.3 Changchun Baike Human Vaccine Sales, Revenue, Price and Gross Margin (2019-2024)
13.15.4 Changchun Baike Main Business Overview
13.15.5 Changchun Baike Latest Developments
13.16 Adimmune
13.16.1 Adimmune Company Information
13.16.2 Adimmune Human Vaccine Product Portfolios and Specifications
13.16.3 Adimmune Human Vaccine Sales, Revenue, Price and Gross Margin (2019-2024)
13.16.4 Adimmune Main Business Overview
13.16.5 Adimmune Latest Developments
13.17 Zhongyianke Biotech
13.17.1 Zhongyianke Biotech Company Information
13.17.2 Zhongyianke Biotech Human Vaccine Product Portfolios and Specifications
13.17.3 Zhongyianke Biotech Human Vaccine Sales, Revenue, Price and Gross Margin (2019-2024)
13.17.4 Zhongyianke Biotech Main Business Overview
13.17.5 Zhongyianke Biotech Latest Developments
13.18 Bharat Biotech
13.18.1 Bharat Biotech Company Information
13.18.2 Bharat Biotech Human Vaccine Product Portfolios and Specifications
13.18.3 Bharat Biotech Human Vaccine Sales, Revenue, Price and Gross Margin (2019-2024)
13.18.4 Bharat Biotech Main Business Overview
13.18.5 Bharat Biotech Latest Developments
13.19 Bavarian Nordic
13.19.1 Bavarian Nordic Company Information
13.19.2 Bavarian Nordic Human Vaccine Product Portfolios and Specifications
13.19.3 Bavarian Nordic Human Vaccine Sales, Revenue, Price and Gross Margin (2019-2024)
13.19.4 Bavarian Nordic Main Business Overview
13.19.5 Bavarian Nordic Latest Developments
13.20 Sanofi-Pasteur
13.20.1 Sanofi-Pasteur Company Information
13.20.2 Sanofi-Pasteur Human Vaccine Product Portfolios and Specifications
13.20.3 Sanofi-Pasteur Human Vaccine Sales, Revenue, Price and Gross Margin (2019-2024)
13.20.4 Sanofi-Pasteur Main Business Overview
13.20.5 Sanofi-Pasteur Latest Developments
13.21 Indian Immunologicals
13.21.1 Indian Immunologicals Company Information
13.21.2 Indian Immunologicals Human Vaccine Product Portfolios and Specifications
13.21.3 Indian Immunologicals Human Vaccine Sales, Revenue, Price and Gross Margin (2019-2024)
13.21.4 Indian Immunologicals Main Business Overview
13.21.5 Indian Immunologicals Latest Developments
13.22 KANGH
13.22.1 KANGH Company Information
13.22.2 KANGH Human Vaccine Product Portfolios and Specifications
13.22.3 KANGH Human Vaccine Sales, Revenue, Price and Gross Margin (2019-2024)
13.22.4 KANGH Main Business Overview
13.22.5 KANGH Latest Developments
13.23 Henan Grand Biopharma
13.23.1 Henan Grand Biopharma Company Information
13.23.2 Henan Grand Biopharma Human Vaccine Product Portfolios and Specifications
13.23.3 Henan Grand Biopharma Human Vaccine Sales, Revenue, Price and Gross Margin (2019-2024)
13.23.4 Henan Grand Biopharma Main Business Overview
13.23.5 Henan Grand Biopharma Latest Developments
13.24 ZhongKe Biopharm
13.24.1 ZhongKe Biopharm Company Information
13.24.2 ZhongKe Biopharm Human Vaccine Product Portfolios and Specifications
13.24.3 ZhongKe Biopharm Human Vaccine Sales, Revenue, Price and Gross Margin (2019-2024)
13.24.4 ZhongKe Biopharm Main Business Overview
13.24.5 ZhongKe Biopharm Latest Developments
13.25 Zhuoyi Biological
13.25.1 Zhuoyi Biological Company Information
13.25.2 Zhuoyi Biological Human Vaccine Product Portfolios and Specifications
13.25.3 Zhuoyi Biological Human Vaccine Sales, Revenue, Price and Gross Margin (2019-2024)
13.25.4 Zhuoyi Biological Main Business Overview
13.25.5 Zhuoyi Biological Latest Developments
14 Research Findings and Conclusion